Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

122.34 +4.90 (+4.17%)
Streaming Delayed Price Updated: 1:15 PM EDT, Jul 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna Inc

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street’s Radar
Discover three under-the-radar pharma stocks poised for significant growth in 2024. Explore their product pipelines and potential gains. 
Via InvestorPlace
Why Moderna Stock Blasted 13% Higher Today
The company notched beats on both the top and bottom lines despite a major drop-off in demand for its famous product. 
Via The Motley Fool
Wall Street Inches Up After Powell's Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What's Driving Markets Thursday?
U.S. stock markets surged during Thursday’s midday trading session in New York, with major averages all showing gains. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Via ACCESSWIRE
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,100 Today
Via Benzinga
Smart Money Is Betting Big In MRNA Options
Via Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars
Moderna reports Q1 loss, beating sales estimates amidst declining COVID-19 vaccine demand. Cost-saving measures drive optimism for investors. CEO Stéphane Bancel eyes strategic investments. Guidance... 
Via Benzinga
Exposures COVID-19
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouraging data from its Phase III gastric cancer treatment trial after... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Moderna (MRNA) Q1 2024 Earnings Call Transcript
MRNA earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
MRNA Stock Earnings: Moderna Beats EPS, Beats Revenue for Q1 2024
MRNA stock results show that Moderna beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Should You Buy Moderna Before May 12?
This ambitious biotech aims to launch 15 products over the coming five years. 
Via The Motley Fool
How Is The Market Feeling About Moderna?
Via Benzinga
Moderna and OpenAI Collaborate To Advance mRNA Medicine
Via ACCESSWIRE
C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Moderna Puts Up Big Quarterly Beat; Could Shares Notch A Breakout?
Moderna is forming its first base in over a year. Could shares top a buy point on the company's sales beat? 
Via Investor's Business Daily
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Cathie Wood Stocks
Current economic tides have turned against Cathie Wood's style of aggressive investing, with three of her picks in particular danger. 
Via InvestorPlace
Shhh! 3 Secret Biotech Stocks Flying Below Wall Street’s Radar
These biotech stocks seem to be rich with intriguing growth plays going for very reasonable multiples this May. 
Via InvestorPlace
Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings: Why This Analyst Thinks 'No Cut' Scenario May Not Be Negative For Market
U.S. stocks look to push ahead on a positive path, now that the Federal Reserve’s rate decision is in the rearview mirror. Major index futures point to a positive open on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition
Here are our top three choices for biotech stocks with blockbuster drug pipelines that could pay off massively in the future. 
Via InvestorPlace
mRNA Is Promising A Breakthrough In Fighting Cancer
When it comes to cancer, there’s innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a genetic material we all got acquainted with during the COVID-19 era as it... 
Via Benzinga
Exposures COVID-19
3 Beaten-Down Stocks I Wouldn't Touch With a 10-Foot Pole
These stocks aren't bargains. 
Via The Motley Fool
Nasdaq Bull Market: Here's the Best Investing Move You Can Make Right Now
Many technology stocks are soaring, and you may be wondering if they've gotten too expensive. 
Via The Motley Fool
All In on Microsoft Stock: How AI Turned MSFT Into the Hottest Tech Play of 2024
Artificial Intelligence is moving Microsoft stock more than even the cloud did, CEO Satya Nadella said, with earnings to prove it. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
What's Going On With Pfizer Stock On Thursday?
GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying high-stakes legal battles in the U.S. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Moderna Stock Jumps On Collaboration With OpenAI: What's Going On?
Moderna began a collaboration with OpenAI in early 2023 with the launch of Moderna's own instance of ChatGPT, called mChat. The company said Wednesday that it has reached more than 80% internal... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
Moderna challenges Pfizer and BioNTech in a London patent trial over mRNA vaccine patents. The outcome may reshape the pharmaceutical landscape, impacting future innovations and revenue streams. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Medical AI Could Be Your Ticket to Riches: 3 Stocks to Buy
With digital intelligence having the capability of advancing care, these are the medical AI stocks that long-term investors should consider. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
REITs Q1 Earnings Begin On Solid Note
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.